Publications by authors named "G R Dieckmann"

Background: Diabetic neuropathy (DN) is a very common clinical condition throughout the world. The diagnostic tests currently recommended have low sensitivity, such as electromyography, or are invasive, such as skin biopsy. New techniques have been developed to identify the early involvement of the peripheral nerve.

View Article and Find Full Text PDF

Introduction: Dry eye disease is characterized by a persistently unstable or deficient tear film causing discomfort or visual impairment. Varenicline is a small-molecule nicotinic acetylcholine receptor agonist recently approved for use as a preservative-free nasal spray (OC-01 [varenicline solution] nasal spray [OC-01 VNS]) to treat signs and symptoms of dry eye disease, but its effect on conjunctival goblet cells has not been studied.

Methods: In this phase 2, single-center, vehicle-controlled study, patients aged 18 years or more with a diagnosis of dry eye disease and Ocular Surface Disease Index score of at least 23 were randomized 2:1 to receive a 50-µL single dose of OC-01 0.

View Article and Find Full Text PDF

Throughout the body, damage to peripheral nerves normally involved in nociception may produce a constellation of symptoms-including irritation, itchiness and pain. The neurobiological processes involved in corneal symptoms of dry eye (DE) and neuropathic corneal pain (NCP) have not been clearly considered in terms of nociceptive processing. The conventional underlying presumption is that a labelled line principle is responsible; that these distinct perceptions are hard coded by primary afferent inputs to the central nervous system.

View Article and Find Full Text PDF
Article Synopsis
  • - This study investigates the effectiveness of low-dose naltrexone (LDN) in treating neuropathic corneal pain (NCP), which can cause symptoms like burning and light sensitivity due to nerve damage.
  • - A group of 59 patients with NCP received LDN for at least four weeks, and the study found a significant reduction in pain scores (nearly 50%) and improvement in quality of life.
  • - The treatment was generally well-tolerated, with minor side effects such as vivid dreams and headaches reported by some patients.
View Article and Find Full Text PDF

Purpose: Neuropathic corneal pain (NCP) is a recently acknowledged disease entity. However, there is no consensus in potential treatment strategies, particularly in patients with a centralized component of pain. This study aims to assess the efficacy and tolerability of the tricyclic antidepressant, nortriptyline, among NCP patients.

View Article and Find Full Text PDF